As one of the pioneers in this field, we have built one of the most robust intellectual property portfolios in nucleic acid-based technology worldwide. As of April 18, 2025, we had a total of 458 patents and patent applications globally, covering major jurisdictions such as China, Europe, the U.S. and Japan, including 229 granted patents and 229 pending applications, in relation to siRNA sequences, chemical modifications, delivery technologies, molecular structures, combination therapies and clinical applications, among others, to protect our technologies and drug assets. Our strong intellectual property portfolio reinforces our leadership in the industry and remains a key driver of our long-term success.

We have developed RiboGalSTAR^TM, RiboOncoSTAR^TM，RiboPepSTAR^TM, dual-targeting and multi-targeting delivery technologies , along with RSC modification technologies, for which we have filed patent applications. Some patents have been granted in jurisdictions such as China, Europe, and the U.S.

We also focus on R&D breakthroughs in dual-targeting and multi-targeting technologies, as well as advanced chemical modification and synthetic technologies. Our RSC technology platform, which is protected by patents in major markets. Through successive generational advancements, it has been systematically optimized for oligonucleotide therapeutic applications

Our intellectual property portfolios also include trade secrets, trademarks and domain names.